Asia Pacific small molecule active pharmaceutical ingredient (API) market will grow by 9.2% annually with a total addressable market cap of $537.3 billion over 2021-2027 owing to increasing incidences of diseases, development of companies engaged in the manufacturing of small molecule APIs, the increasing technological developments in manufacturing sector, and surge in healthcare expenditure amid COVID-19 pandemic.
Highlighted with 33 tables and 52 figures, this 112-page report “Asia Pacific Small Molecule API Market 2020-2027 by Source (Synthetic, Semi-synthetic, Natural), Type (Standard, HPAPI), Therapeutic Area, Application (Clinical, Commercial), Manufacturer Type (Pharma, CMO), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific small molecule API market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:

  • Market Structure
  • Growth Drivers
  • Restraints and Challenges
  • Emerging Product Trends & Market Opportunities
  • Porter’s Fiver Forces


The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific small molecule API market in every aspect of the classification from perspectives of Source, Type, Therapeutic Area, Application, Manufacturer Type, and Country.

Based on Source, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2017-2027 included in each section.

  • Synthetic API


o Branded Synthetic API
o Generic Synthetic API

  • Semi-synthetic API
  • Natural Origin



Based on Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2017-2027 included in each section.

  • Standard API
  • High Potency API (HPAPI)


o Branded HPAPI
o Generic HPAPI

Based on Therapeutic Area, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2017-2027 included in each section.

  • Infectious Diseases
  • Oncology
  • Ophthalmology
  • Cardiovascular Disorders
  • Central Nervous System
  • Respiratory Disorders
  • Metabolic Diseases
  • Other Applications



Based on Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2017-2027 included in each section.
o Clinical Use
o Commercial Use

Based on Manufacturer Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2017-2027 included in each section.

  • Pharmaceutical Companies
  • CMOs



Geographically, the following national/local markets are fully investigated:

  • Japan
  • China
  • South Korea
  • Australia
  • India
  • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)


For each key country, detailed analysis and data for annual revenue ($ bn) are available for 2017-2027. The breakdown of key national markets by Type, Therapeutic Area, and Manufacturer Type over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Key Players (this may not be a complete list and extra companies can be added upon request):
Aurobindo Pharma Ltd.
Cambrex Corporation
Catalent, Inc.
Dr. Reddy’s Laboratories Ltd.
GlaxoSmithKline plc
Lonza Group
Merck & Co., Inc.
Mylan N.V.
Novartis AG
Pfizer Inc.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Wuxi AppTec Co., Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)